Facial myokymia
Methodology & AI Transparency ⓘ
Facial myokymia Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Physicians managing Facial myokymia (G51.4; Neurology, Stroke & Movement Disorders) utilize sensorimotor neurologic examination [Facial myokymia G51.4] and objective HbA1c & Blood in Facial myokymia (G51.4: Pressure Neuro-Targets) targets (BP < 120/75 mmHg; HbA1c < 5.7% (G51.4)) to prevent progression and functional morbidity.
- 2 Real-world patient consensus: Mapped to Neurology, Stroke & Movement Disorders under ICD-10-CM G51.4 for Facial myokymia clinical workups.
- 3 Typical cash cost range: Clinicians assessing Facial myokymia focus on or basal ganglia in Facial myokymia (G51.4: dopaminergic circuit degeneration) and targeted history.
- 4 Top reported side effects / signs: Objective lab/clinical target for Facial myokymia: HbA1c & Blood in Facial myokymia (G51.4: Pressure Neuro-Targets) (BP < 120/75 mmHg; HbA1c < 5.7% (G51.4)) and Serum Vitamin B12 in Facial myokymia (G51.4: & Methylmalonic Acid).
Ask our AI Specialists anything about Facial myokymia
What Is Facial myokymia?
Physicians managing Facial myokymia (G51.4; Neurology, Stroke & Movement Disorders) utilize sensorimotor neurologic examination [Facial myokymia G51.4] and objective HbA1c & Blood in Facial myokymia (G51.4: Pressure Neuro-Targets) targets (BP < 120/75 mmHg; HbA1c < 5.7% (G51.4)) to prevent progression and functional morbidity.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Facial myokymia (ICD-10 G51.4) is driven by or basal ganglia in Facial myokymia (G51.4: dopaminergic circuit degeneration); specialists in Neurology, Stroke & Movement Disorders monitor Serum Vitamin B12 in Facial myokymia (G51.4: & Methylmalonic Acid) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Facial myokymia (G51.4): numbness, paresthesia, or in Facial myokymia (G51.4: visual field/speech changes)
- • Secondary Facial myokymia clinical sign: muscle stiffness, spasticity, in Facial myokymia (G51.4: or fatigable neuromuscular)
- • Symptom flares in Facial myokymia correlating with HbA1c & Blood in Facial myokymia (G51.4: Pressure Neuro-Targets) deviation outside BP < 120/75 mmHg; HbA1c < 5.7% (G51.4)
- • Functional brain & neurology impact requiring sensorimotor neurologic examination [Facial myokymia G51.4] evaluation (G51.4)
Facial myokymia Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | G51.4 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Neurology, Stroke & Movement Disorders | NLM Clinical Tables |
| Diagnostic / Lab Marker: HbA1c & Blood in Facial myokymia (G51.4: Pressure Neuro-Targets) | BP < 120/75 mmHg; HbA1c < 5.7% (G51.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Vitamin B12 in Facial myokymia (G51.4: & Methylmalonic Acid) | B12 > 500 pg/mL; MMA < 240 nmol/L (G51.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Carotid Duplex / in Facial myokymia (G51.4: Cerebral Perfusion) | No hemodynamically significant stenosis (G51.4) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Facial myokymia
Treatment selection for Facial myokymia depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Facial myokymia)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Aesthetic Improvements Over Time: Long-Term Efficacy and Additional Outcomes of Additional endpoints, including pGAIS, iGAIS, and MAS scores, corroborate prior ULTRAI/II findings and demonstrate the efficacy of incobotulinumtoxinA for simultaneous treatment of UFLs. Journal of cosmetic dermatology • 2025-09-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40968493 ↗ |
| Can This Approach Help? Inside the Latest Research on Validation of the Index for Facial Angiofibromas: Data analysis from a randomized The IFA score is potentially clinically useful because of its high validity and reliability. The Journal of dermatology • 2024-06-15 • Phase III Randomized Trial | N = 62 | 88/100 | PMID 38619178 ↗ |
| Can This Approach Help? Inside the Latest Research on IncobotulinumtoxinA in the Treatment of Upper Facial Lines: Results From Two In ULTRA I and ULTRA II, the safety and real-world benefits of incobotulinumtoxinA for the simultaneous treatment of moderate-to-severe UFLs were demonstrated, with significant improvements. Aesthetic surgery journal • 2025-02-18 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39475143 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of Combined skin-applied Lidocaine and Tetracaine Cream for This study demonstrated the equivalent efficacy of CU-30101 to its reference product, Pliaglis, among Chinese adults undergoing facial fractional laser resurfacing. Journal of cosmetic dermatology • 2025-08-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40735955 ↗ |
| Can This Approach Help? Inside the Latest Research on Multiple sclerosis clinical decision support system based on projection to The pioneer use of PORs for each individual patient enables personalized analytics sustaining the dialog between neurologists, patients and caregivers with quantified evidence. Annals of clinical and translational neurology • 2022-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 36412095 ↗ |
Facial myokymia Patient Community & “People Like Me” Threads
Filter Facial myokymia community threads and patient logs by age, biological sex, dosage, and treatment duration.